Analysts expect that Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) will announce ($0.74) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have provided estimates for Eiger Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.60) and the lowest estimate coming in at ($0.83). Eiger Biopharmaceuticals posted earnings per share of ($1.10) in the same quarter last year, which would indicate a positive year over year growth rate of 32.7%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 8th.
According to Zacks, analysts expect that Eiger Biopharmaceuticals will report full-year earnings of ($2.98) per share for the current year, with EPS estimates ranging from ($3.35) to ($2.71). For the next financial year, analysts expect that the business will post earnings of ($3.14) per share, with EPS estimates ranging from ($3.82) to ($2.60). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Eiger Biopharmaceuticals.
Eiger Biopharmaceuticals (NASDAQ:EIGR) last announced its quarterly earnings data on Friday, August 10th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.82).
A number of analysts have recently issued reports on EIGR shares. LADENBURG THALM/SH SH set a $28.00 price objective on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 17th. ValuEngine cut shares of Eiger Biopharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 17th. Wedbush set a $53.00 price objective on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Monday, September 10th. Oppenheimer set a $26.00 price objective on shares of Eiger Biopharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, August 14th. Finally, Zacks Investment Research raised shares of Eiger Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research note on Tuesday, July 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $29.71.
In related news, major shareholder Interwest Partners X. Lp sold 237,265 shares of the firm’s stock in a transaction on Thursday, October 18th. The shares were sold at an average price of $12.06, for a total transaction of $2,861,415.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 7.90% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of EIGR. Northern Trust Corp grew its stake in Eiger Biopharmaceuticals by 169.7% during the first quarter. Northern Trust Corp now owns 29,376 shares of the biotechnology company’s stock valued at $289,000 after acquiring an additional 18,483 shares in the last quarter. BlackRock Inc. lifted its position in Eiger Biopharmaceuticals by 181.0% during the first quarter. BlackRock Inc. now owns 80,912 shares of the biotechnology company’s stock valued at $797,000 after purchasing an additional 52,114 shares during the last quarter. Acadian Asset Management LLC lifted its position in Eiger Biopharmaceuticals by 171.2% during the second quarter. Acadian Asset Management LLC now owns 56,266 shares of the biotechnology company’s stock valued at $687,000 after purchasing an additional 35,518 shares during the last quarter. Algert Global LLC bought a new position in Eiger Biopharmaceuticals during the second quarter valued at $277,000. Finally, Jennison Associates LLC lifted its position in Eiger Biopharmaceuticals by 93.3% during the second quarter. Jennison Associates LLC now owns 1,256,501 shares of the biotechnology company’s stock valued at $15,329,000 after purchasing an additional 606,361 shares during the last quarter. 69.64% of the stock is owned by institutional investors.
Shares of NASDAQ EIGR traded down $1.19 during midday trading on Monday, reaching $10.70. The stock had a trading volume of 62,490 shares, compared to its average volume of 138,484. The company has a debt-to-equity ratio of 0.35, a current ratio of 8.49 and a quick ratio of 8.49. The stock has a market cap of $169.36 million, a PE ratio of -2.20 and a beta of 1.81. Eiger Biopharmaceuticals has a 12-month low of $7.46 and a 12-month high of $18.00.
Eiger Biopharmaceuticals Company Profile
Eiger BioPharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare diseases in the United States and internationally. The company's lead program is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trial for treating hepatitis delta virus (HDV) infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.